Literature DB >> 8095198

Association between ICAM-1 expression and metastatic capacity of murine B-cell hybridomas.

R G Hawley1, M H Wang, A Z Fong, T S Hawley.   

Abstract

We previously reported that a derivative of the interleukin-6 (IL-6)-dependent B9 B-cell hybridoma (B9/LPNU1L) constitutively expressing an interleukin-1 alpha (IL-1 alpha) gene introduced by retrovirus-mediated gene transfer preferentially metastasized to bone marrow following intravenous injection into unirradiated syngeneic BALB/c mice. B9/LPNU1L cells recovered from the femoral marrow of a recipient with hind limb paralysis (denoted B9/BM1) retained their IL-6-dependency yet displayed enhanced metastatic capacity during serial transplantation in vivo. In contrast, autonomously-growing B9 variants spontaneously arising in vitro or IL-6-independent B9 derivatives created by infection with recombinant IL-6 retroviruses rarely gave rise to experimental metastases in syngeneic BALB/c or nude mice. Examination of cell adhesion molecule profiles by immunofluorescence flow cytometry has revealed high levels of CD44, moderate levels of VLA-4 and low levels of LFA-1 on all B9-series cells. By comparison, ICAM-1 expression was significantly elevated on B9/BM1 cells, with independent isolates stably expressing about 4-fold higher levels which were paralleled by corresponding increases in the steady-state levels of ICAM-1 mRNA. L-Selectin was not expressed by any of the cell lines. Despite higher ICAM-1 levels, cell aggregation assays revealed that LFA-1-ICAM-1 adhesive interactions were not involved in the homotypic adhesion of B9/BM1 cells but rather that binding of CD44 to endogenously-synthesized hyaluronan was responsible. Furthermore, B9/BM1 cells expressing high levels of ICAM-1 were found to be less susceptible to cytolysis by natural killer (NK) cells than their weakly metastatic or nonmetastatic counterparts.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8095198     DOI: 10.1007/bf00114979

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  54 in total

1.  Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma.

Authors:  X G Zhang; B Klein; R Bataille
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

2.  Interleukin-2 augments natural killer cell activity.

Authors:  C S Henney; K Kuribayashi; D E Kern; S Gillis
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

3.  Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity.

Authors:  J C Becker; R Dummer; A A Hartmann; G Burg; R E Schmidt
Journal:  J Immunol       Date:  1991-12-15       Impact factor: 5.422

4.  In vivo effect of anti-asialo GM1 antibody on natural killer activity.

Authors:  M Kasai; T Yoneda; S Habu; Y Maruyama; K Okumura; T Tokunaga
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

5.  Binding of hyaluronic acid to lymphoid cell lines is inhibited by monoclonal antibodies against Pgp-1.

Authors:  J Lesley; R Schulte; R Hyman
Journal:  Exp Cell Res       Date:  1990-04       Impact factor: 3.905

6.  Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection.

Authors:  R Wallich; N Bulbuc; G J Hämmerling; S Katzav; S Segal; M Feldman
Journal:  Nature       Date:  1985 May 23-29       Impact factor: 49.962

Review 7.  Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites.

Authors:  G L Nicolson
Journal:  Cancer Metastasis Rev       Date:  1988-06       Impact factor: 9.264

8.  Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors.

Authors:  H Karasuyama; F Melchers
Journal:  Eur J Immunol       Date:  1988-01       Impact factor: 5.532

9.  Molecular cloning and expression of Pgp-1. The mouse homolog of the human H-CAM (Hermes) lymphocyte homing receptor.

Authors:  D F Zhou; J F Ding; L J Picker; R F Bargatze; E C Butcher; D V Goeddel
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

10.  Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition.

Authors:  K Miyake; C B Underhill; J Lesley; P W Kincade
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

View more
  6 in total

1.  Significance of VLA-4-VCAM-1 interaction and CD44 for transendothelial invasion in a bone marrow metastatic myeloma model.

Authors:  T Okada; R G Hawley; M Kodaka; H Okuno
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

Review 2.  Hyaluronan in immune dysregulation and autoimmune diseases.

Authors:  Nadine Nagy; Hedwich F Kuipers; Payton L Marshall; Esther Wang; Gernot Kaber; Paul L Bollyky
Journal:  Matrix Biol       Date:  2018-04-04       Impact factor: 11.583

Review 3.  Are cellular adhesion molecules involved in the metastasis of breast cancer?

Authors:  M Maemura; R B Dickson
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

4.  Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells.

Authors:  Tomoko Okada; Shingo Akikusa; Hiroaki Okuno; Masato Kodaka
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

Review 5.  CD44: physiological expression of distinct isoforms as evidence for organ-specific metastasis formation.

Authors:  M Zöller
Journal:  J Mol Med (Berl)       Date:  1995-09       Impact factor: 4.599

Review 6.  Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.

Authors:  Alessandro Allegra; Vanessa Innao; Andrea Gaetano Allegra; Marta Pugliese; Eleonora Di Salvo; Elvira Ventura-Spagnolo; Caterina Musolino; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2019-06-10       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.